Cuba launches clinic for chikungunya aftereffects

The Institute of Neurology and Neurosurgery in Cuba has begun a specialized clinic to care for patients with post-chikungunya ailments, particularly those linked to neuropathic pain, joint pain, and paresthesia. This step provides focused treatment for individuals impacted by the mosquito-borne virus.

In Havana on December 23, the Institute of Neurology and Neurosurgery in Cuba has launched a specialized clinic dedicated to treating patients with post-chikungunya ailments. The facility focuses on conditions such as neuropathic pain, joint pain, and paresthesia, which are common lingering effects of the mosquito-borne chikungunya virus that causes fever and severe aches.

Chikungunya can lead to long-term complications that impair daily life for those infected. The new clinic aims to address these persistent issues through comprehensive care. As reported by Prensa Latina, this opening meets the demand for specialized health services in Cuba.

While specific patient numbers are not yet available, the clinic is part of Cuba's public health efforts to manage infectious diseases and their neurological aftermaths. This initiative highlights Cuba's dedication to accessible medical treatment for virus-related conditions.

Связанные статьи

Comparative illustration of long COVID patients: US woman with severe brain fog and anxiety versus milder symptoms in India, Nigeria, and Colombia, per international study.
Изображение, созданное ИИ

International study finds U.S. long COVID patients report more brain fog and psychological symptoms than peers in India and Nigeria

Сообщено ИИ Изображение, созданное ИИ Проверено фактами

A Northwestern Medicine-led study of more than 3,100 adults with long COVID found that non-hospitalized participants in the United States reported substantially higher rates of brain fog, depression/anxiety and insomnia than participants in Colombia, Nigeria and India—differences the researchers say likely reflect cultural factors and access to care as much as biology.

Cuban President Miguel Díaz-Canel presented preliminary positive results from clinical trials of the biotechnological drug Jusvinza in patients with chronic post-chikungunya arthritis. The studies, started in December 2025, show notable improvements in provinces like Havana and Matanzas. Experts highlight the drug's safety profile and potential to slow inflammation.

Сообщено ИИ

Cuba has a favorable epidemiological situation in its fight against arboviruses, following a 21 percent decrease in reported febrile cases last week. This improvement highlights effective efforts to control vector-borne diseases such as dengue and zika. Health authorities emphasize the need for ongoing vigilance.

New research challenges long-standing concerns about the antiviral drug oseltamivir, known as Tamiflu, and its potential link to serious neuropsychiatric events in children. Instead, the study attributes such symptoms to the influenza virus itself and shows that Tamiflu treatment halves the risk of these complications. The findings, based on a large analysis of pediatric health records, aim to reassure families and doctors about the drug's safety.

Сообщено ИИ

A genetic technology called a gene drive has shown promise in preventing malaria transmission by mosquitoes during lab tests in Tanzania. Researchers modified local mosquitoes to produce antimalarial proteins, demonstrating effective inhibition of parasites from infected children. The findings suggest the approach could work in the field if released.

The Hatuey Project, a U.S.-based solidarity initiative, delivered donations of supplies and medications for pediatric cancer treatment to two Cuban hospitals. This marks the eighth time they have supported the island's health system amid the U.S. economic blockade. The project's coordinator reaffirmed an unwavering commitment to Cuba during an event in Havana.

Сообщено ИИ Проверено фактами

Scientists at the University of Queensland have captured the first near‑atomic, high‑resolution 3D images of the yellow fever virus, detailing how the surface of the long‑used vaccine strain differs from virulent, disease‑causing strains. The work sheds light on how the virus is recognised by the immune system and could support improved vaccines for yellow fever and related mosquito‑borne diseases.

 

 

 

Этот сайт использует куки

Мы используем куки для анализа, чтобы улучшить наш сайт. Прочитайте нашу политику конфиденциальности для дополнительной информации.
Отклонить